X-Linked Lymphoproliferative Syndrome : A Spectrum of Clinical and Immunological Profile and Novel Pathogenic Variants from Chandigarh, India
© 2024 S. Karger AG, Basel..
INTRODUCTION: X-linked lymphoproliferative syndrome (XLP) is a rare primary immune deficiency. Two types of XLP have been described: XLP-1 and XLP-2.
METHODS: We found 7 patients with XLP (3 had XLP-1 and 4 had XLP-2) after reviewing the data from Pediatric Immunodeficiency Clinic from 1997 to 2021.
RESULTS: Mean age at diagnosis was 3.8 years, and mean delay in diagnosis was 2.6 years. Five patients had recurrent episodes of infections. Four patients developed at least one episode of hemophagocytic lymphohistiocytosis (HLH) (2 with XLP-1 and 2 with XLP-2). Of these, 2 had recurrent HLH (both with XLP-2). Epstein-Barr virus (EBV) infection was detected in 2 (1 with XLP-1 and 1 with XLP-2). Both these patients had HLH. One child with XLP-2 had inflammatory bowel disease. Hypogammaglobulinemia was seen in 3 (2 with XLP-1 and 1 with XLP-2). Genetic analysis showed previously reported variants in 5, while 2 had novel variants (one in exon 7 of XIAP gene [c.1370dup p.Asn457Lysfs Ter16] and other had splice site variant in intron 1 of SH2D1A gene [c.138-2_138-1insG]). Episodes of HLH were managed with intravenous immunoglobulin (IVIg), methylprednisolone, oral prednisolone, cyclosporine, and rituximab. Inflammatory bowel disease was managed using oral prednisolone and azathioprine. One patient underwent haploidentical hematopoietic stem cell transplantation. One child with XLP-2 and WAS died because of fulminant pneumonia.
DISCUSSION/CONCLUSIONS: XLP should be considered as a strong possibility in any patient with features of HLH, repeated infections with hypogammaglobulinemia, persistent EBV infection, and early-onset IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
|---|---|
| Enthalten in: |
International archives of allergy and immunology - 185(2024), 4 vom: 17., Seite 370-381 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jindal, Ankur Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000531296 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366855379 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366855379 | ||
| 003 | DE-627 | ||
| 005 | 20240417232352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000531296 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM366855379 | ||
| 035 | |a (NLM)38194943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jindal, Ankur Kumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a X-Linked Lymphoproliferative Syndrome |b A Spectrum of Clinical and Immunological Profile and Novel Pathogenic Variants from Chandigarh, India |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: X-linked lymphoproliferative syndrome (XLP) is a rare primary immune deficiency. Two types of XLP have been described: XLP-1 and XLP-2 | ||
| 520 | |a METHODS: We found 7 patients with XLP (3 had XLP-1 and 4 had XLP-2) after reviewing the data from Pediatric Immunodeficiency Clinic from 1997 to 2021 | ||
| 520 | |a RESULTS: Mean age at diagnosis was 3.8 years, and mean delay in diagnosis was 2.6 years. Five patients had recurrent episodes of infections. Four patients developed at least one episode of hemophagocytic lymphohistiocytosis (HLH) (2 with XLP-1 and 2 with XLP-2). Of these, 2 had recurrent HLH (both with XLP-2). Epstein-Barr virus (EBV) infection was detected in 2 (1 with XLP-1 and 1 with XLP-2). Both these patients had HLH. One child with XLP-2 had inflammatory bowel disease. Hypogammaglobulinemia was seen in 3 (2 with XLP-1 and 1 with XLP-2). Genetic analysis showed previously reported variants in 5, while 2 had novel variants (one in exon 7 of XIAP gene [c.1370dup p.Asn457Lysfs Ter16] and other had splice site variant in intron 1 of SH2D1A gene [c.138-2_138-1insG]). Episodes of HLH were managed with intravenous immunoglobulin (IVIg), methylprednisolone, oral prednisolone, cyclosporine, and rituximab. Inflammatory bowel disease was managed using oral prednisolone and azathioprine. One patient underwent haploidentical hematopoietic stem cell transplantation. One child with XLP-2 and WAS died because of fulminant pneumonia | ||
| 520 | |a DISCUSSION/CONCLUSIONS: XLP should be considered as a strong possibility in any patient with features of HLH, repeated infections with hypogammaglobulinemia, persistent EBV infection, and early-onset IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epstein-Barr virus | |
| 650 | 4 | |a Hemophagocytic lymphohistiocytosis | |
| 650 | 4 | |a Hypogammaglobulinemia | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Multisystemic inflammatory syndrome in children | |
| 650 | 4 | |a X-linked lymphoproliferative disease | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 700 | 1 | |a Mondal, Sanjib |e verfasserin |4 aut | |
| 700 | 1 | |a Sil, Archan |e verfasserin |4 aut | |
| 700 | 1 | |a Rawat, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Chawla, Sanchi |e verfasserin |4 aut | |
| 700 | 1 | |a Tyagi, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Sudhakar, Murugan |e verfasserin |4 aut | |
| 700 | 1 | |a Banday, Aaqib Zaffar |e verfasserin |4 aut | |
| 700 | 1 | |a Suri, Deepti |e verfasserin |4 aut | |
| 700 | 1 | |a Vignesh, Pandiarajan |e verfasserin |4 aut | |
| 700 | 1 | |a Dhaliwal, Manpreet |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Saniya |e verfasserin |4 aut | |
| 700 | 1 | |a Rikhi, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Saka, Ruchi |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Rajni |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Debajyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Sreedharanunni, Sreejesh |e verfasserin |4 aut | |
| 700 | 1 | |a Uppuluri, Ramya |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, Revathi |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Surjit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International archives of allergy and immunology |d 1992 |g 185(2024), 4 vom: 17., Seite 370-381 |w (DE-627)NLM012632554 |x 1423-0097 |7 nnns |
| 773 | 1 | 8 | |g volume:185 |g year:2024 |g number:4 |g day:17 |g pages:370-381 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000531296 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 185 |j 2024 |e 4 |b 17 |h 370-381 | ||